naulicreative / Shutterstock.com
The consequences of the Brexit vote for the life sciences sector will depend on the UK’s relationship with the EU once the negotiations are concluded, as Christina Guazzi and Nina Schäffner of Freshfields Bruckhaus Deringer explain.
One potential outcome of the British vote to leave the EU is the divergence of regulatory frameworks for bringing pharmaceutical products to market in the UK and the EU—UK IP rights may split from harmonised EU systems of protection.
UK life sciences companies will be hit hardest by these changes but they are also set to affect all major EU and international players with activities across the UK and the EU.
Of course, much will depend on the UK’s relationship with the EU once Brexit negotiations are concluded. If the UK remains in the European Economic Area (EEA), then the adjustments for the pharmaceutical industry are likely to be less significant.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Christina Guazzi, Nina Schäffner, Freshfields Bruckhaus Deringer, S[Cs, EEA, Brexit, life sciences, UPC, market exclusivity, EMA, MHRA, patent,